MRK1

111.6

+0.36%↑

SHL.DE

46.45

+0.13%↑

ARGX

489.5

-0.61%↓

FRE

40.98

-0.07%↓

ONC.US

298.95

+1.5%↑

MRK1

111.6

+0.36%↑

SHL.DE

46.45

+0.13%↑

ARGX

489.5

-0.61%↓

FRE

40.98

-0.07%↓

ONC.US

298.95

+1.5%↑

MRK1

111.6

+0.36%↑

SHL.DE

46.45

+0.13%↑

ARGX

489.5

-0.61%↓

FRE

40.98

-0.07%↓

ONC.US

298.95

+1.5%↑

MRK1

111.6

+0.36%↑

SHL.DE

46.45

+0.13%↑

ARGX

489.5

-0.61%↓

FRE

40.98

-0.07%↓

ONC.US

298.95

+1.5%↑

MRK1

111.6

+0.36%↑

SHL.DE

46.45

+0.13%↑

ARGX

489.5

-0.61%↓

FRE

40.98

-0.07%↓

ONC.US

298.95

+1.5%↑

Search

Sanofi SA

Open

SectorHealthcare

83.2 -0.08

Overview

Share price change

24h

Current

Min

83.05

Max

83.79

Key metrics

By Trading Economics

Income

1.4B

1.9B

Sales

3B

11B

P/E

Sector Avg

16.742

39.857

EPS

1.79

Dividend yield

4.77

Profit margin

17.65

Employees

82,878

EBITDA

2.2B

2.8B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+33.66% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.77%

2.42%

Next Earnings

31 Jul 2025

Market Stats

By TradingEconomics

Market Cap

-28B

102B

Previous open

83.28

Previous close

83.2

News Sentiment

By Acuity

36%

64%

125 / 376 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Sanofi SA Chart

Past performance is not a reliable indicator of future results.

Related News

1 Jul 2025, 19:16 UTC

Acquisitions, Mergers, Takeovers

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 Jul 2025, 12:03 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Adagene ADRs Rise Following Sanofi Investment

30 Jun 2025, 14:30 UTC

Acquisitions, Mergers, Takeovers

Santander Submits Binding Offer for Sabadell's TSB Unit, Reuters Says, Citing Sources

19 Jun 2025, 07:27 UTC

Acquisitions, Mergers, Takeovers

Barclays, Santander Interested in Sabadell's U.K. Unit TSB, Bloomberg Says, Citing Sources

11 Jun 2025, 08:25 UTC

Acquisitions, Mergers, Takeovers

EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio

2 Jun 2025, 16:05 UTC

Major Market Movers

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6

9 Jul 2025, 10:59 UTC

Market Talk

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9 Jul 2025, 09:17 UTC

Hot Stocks

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

7 Jul 2025, 12:06 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Santander's TSB Purchase Should Help Improve U.K. Risk Profile -- Market Talk

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Received All Required Authorizations

4 Jul 2025, 15:48 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 Jul 2025, 15:47 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Agreement Was Announced on Dec. 19

4 Jul 2025, 15:47 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 Jul 2025, 15:46 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

3 Jul 2025, 08:25 UTC

Market Talk
Acquisitions, Mergers, Takeovers

BBVA Challenged With Enticing Enough Sabadell Shareholders to Support Takeover -- Market Talk

3 Jul 2025, 07:03 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Sabadell's TSB Sale Doesn't Alter Strategic Rationale for BBVA Bid -- Market Talk

2 Jul 2025, 11:59 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Santander's TSB Purchase to Help Solve U.K. Profitability Drag -- Market Talk

2 Jul 2025, 11:48 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Spanish Banks in M&A Triangle Over TSB Deal -- Market Talk

2 Jul 2025, 06:08 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Sabadell's TSB Sale to Santander Is Win-Win Deal -- Market Talk

2 Jul 2025, 05:34 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Santander's Acquisition of Sabadell's TSB Is Somewhat Surprising -- Market Talk

1 Jul 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 Jul 2025, 16:55 UTC

Earnings

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

27 Jun 2025, 09:13 UTC

Market Talk

Santander Is Cheap and Has Catalysts Ahead -- Market Talk

20 Jun 2025, 08:36 UTC

Market Talk

Predictability of U.K. Banks Has Value -- Market Talk

20 Jun 2025, 07:10 UTC

Market Talk

Strong Correction Unlikely for Spanish Banks -- Market Talk

10 Jun 2025, 12:18 UTC

Earnings

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

2 Jun 2025, 13:50 UTC

Earnings
Acquisitions, Mergers, Takeovers

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 Jun 2025, 12:33 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Sanofi Portfolio Approach Awaits Proof of Improvement -- Market Talk

Peer Comparison

Price change

Sanofi SA Forecast

Price Target

By TipRanks

33.66% upside

12 Months Forecast

Average 111.203 EUR  33.66%

High 127 EUR

Low 95 EUR

Based on 16 Wall Street analysts offering 12 month price targets forSanofi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

16 ratings

11

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

91.3 / 96.1Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

125 / 376 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.